Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the Price/OCF ratio high or low?
The Price/OCF ratio of 26.56 is in line with its estimated 1-year average of 28.16, near the low end of its estimated 1-year range (25.56–31.05).
As of 2026-10-06T18:26:54.519Z.
Calculation as of: 2026-10-06T18:26:54.519Z.
Quote observation: 2026-10-06T17:49:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dac276dab9b72f767ef95dff0a018bdb1655164ea652fec6d95688d7a2c4747
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
26.56
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
17.18
median of 235 covered companies
CURRENT VS SECTOR MEDIAN
+54.60%
vs the sector median at left
Vyome Holdings, Inc.
Market Cap
$13.93M
Price/OCF Ratio
26.56
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Vyome Holdings, Inc. (HIND) | $13.93M | 26.56 |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.01M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.78M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.40M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.18M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.71M | N/A |
| Jin Medical International Ltd. (ZJYL)vs › | $15.11M | N/A |
P/OCF Ratio
26.6
P/FCF Ratio
26.6
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2026-10-05 | 25.83 |
| 2026-10-02 | 25.56 |
| 2026-10-01 | 25.69 |
| 2026-09-30 | 25.83 |
| 2026-09-29 | 27.03 |
| 2026-09-28 | 27.17 |
| 2026-09-25 | 27.30 |
| 2026-09-24 | 27.57 |
| 2026-09-23 | 26.90 |
| 2026-09-22 | 26.10 |
| 2026-09-21 | 25.83 |
| 2026-09-18 | 28.10 |
| 2026-09-17 | 26.23 |
| 2026-09-16 | 26.10 |
| 2026-09-15 | 26.90 |
| 2026-09-14 | 27.57 |
| 2026-09-11 | 27.57 |
| 2026-09-10 | 28.10 |
| 2026-09-09 | 27.57 |
| 2026-09-08 | 27.97 |
| 2026-09-04 | 29.71 |
| 2026-09-03 | 29.84 |
| 2026-09-02 | 29.17 |
| 2026-09-01 | 29.04 |
| 2026-08-31 | 28.91 |
| 2026-08-28 | 29.57 |
| 2026-08-27 | 29.57 |
| 2026-08-26 | 28.91 |
| 2026-08-25 | 29.84 |
| 2026-08-24 | 29.98 |
| 2026-08-21 | 30.11 |
| 2026-08-20 | 30.51 |
| 2026-08-19 | 31.05 |
| 2026-08-18 | 30.38 |
| 2026-08-17 | 30.38 |
| 2026-08-14 | 29.17 |
| 2026-08-13 | 28.91 |
